New COVID-19 mutant in Bengal, escapes antibodies' immunity : Bulletin: Business Today
Business Today
Loading...
 

New COVID-19 mutant in Bengal, escapes antibodies' immunity

Loading the player...

Rashi Bisaria | April 22, 2021

New COVID-19 mutant in Bengal, escapes antibodies' immunity

Scientists have found a new lineage of the SARS-CoV-2 virus named 'B.1.618' in India, which is predominantly circulating in West Bengal. This is the second lineage to be identified from the country. The infection through this variant makes plasma therapy as redundant as an investigational treatment.

600% jump in oxygen demand from hospitals

Putting tremendous pressure on the nation's medical infrastructure, the latest surge in COVID-19 cases has driven up the demand for medical oxygen, a critical commodity in treating the respiratory ailment. The demand for oxygen in hospitals has reportedly gone up 600-800 per cent over the past few days. During the first COVID-19 wave, the demand for liquid medical oxygen went up from 700 metric tonnes per day (MTPD) to 2,800 MTPD. But during the second wave, it has further skyrocketed to 5,000 MTPD, reported India Today.

COVID-19 vaccination: India needs 8 yrs 9 months to achieve herd immunity

At the current pace of vaccination against coronavirus, India would need another 8 years and 9 months to inoculate 70 per cent of its entire population, a threshold required to achieve herd immunity. As of April 20, approximately 10.97 crore Indians have received the first dose of one of two coronavirus vaccines approved for use in the country. This accounts for a mere 8.09 per cent of the nation's 135.5 crore population.

CARE Ratings cuts India's GDP forecast to 10.2% for FY22With economic activities getting affected across the country due to curbs imposed by states amid surge in COVID-19 cases, Care Ratings has revised down its forecast for GDP growth to 10.2 per cent in 2021-22 from earlier projection of 10.7-10.9 per cent. This is the third revision by the rating agency in the last one month.

Bharat Biotech's Covaxin 78% effective; works against most COVID-19 variants

Bharat Biotech's COVID-19 vaccine has shown an overall interim clinical efficacy of 78 per cent and 100 per cent efficacy against severe COVID-19 disease. ""Efficacy against SARS-Cov-2 has been established. COVAXIN has demonstrated an excellent safety record in human clinical trials and in usage under emergency use," Dr Krishna Ella, Chairman & Managing Director, Bharat Biotech, said.

Keep border issue at 'appropriate position', focus on long term ties: China to India

China said on Wednesday that it was committed to maintain peace and stability along the Line of Actual Control (LAC) as it urged India to put the boundary issue at an "appropriate position" and meet it "halfway" for the long term development of the bilateral ties. Chinese Foreign Ministry spokesman Wang Wenbin said this at his media briefing as he parried questions

More from this section